(ERF) Eurofins Scientific SE - Ratings and Ratios

Eurofins Scientific SE is a global leader in analytical testing and laboratory services, operating across various sectors including agroscience, biopharma, clinical diagnostics, consumer products, and environmental testing. The companys extensive service portfolio encompasses biological assessments, product chemistry, regulatory consultancy, and seed services, among others. With a strong presence in the biotechnology industry, Eurofins has established itself as a trusted provider of high-quality testing and laboratory services, catering to the needs of diverse clients worldwide.

From a technical analysis perspective, Eurofins stock has demonstrated a bullish trend, with its last price of 56.96 EUR being above its 20-day simple moving average (SMA) of 56.62 EUR. The stock has also outperformed its 50-day SMA of 53.16 EUR and 200-day SMA of 50.33 EUR, indicating a strong upward momentum. The average true range (ATR) of 1.08 EUR, representing 1.90% of the last price, suggests moderate volatility. With a 52-week high of 58.76 EUR and a low of 43.24 EUR, the stock is currently trading near its 52-week high, indicating a potential for consolidation or a pullback.

Fundamentally, Eurofins Scientific SE has a market capitalization of 10.48 billion EUR, with a price-to-earnings (P/E) ratio of 28.11 and a forward P/E of 14.29. The companys return on equity (RoE) stands at 10.82%, indicating a relatively strong profitability. Considering the P/E ratio and RoE, Eurofins appears to be reasonably valued, with a potential for long-term growth.

Forecasting Eurofins stock performance using a combination of technical and fundamental data, we can expect the stock to continue its upward trend in the short term, potentially reaching 60 EUR. However, the high P/E ratio and nearing 52-week high may lead to a consolidation phase, with a potential pullback to 54 EUR. In the long term, Eurofins strong fundamentals, including its diversified service portfolio and robust financials, are likely to drive the stock price higher, potentially reaching 65 EUR within the next 12-18 months.